Last reviewed · How we verify
topical desonide hydrogel 0.05%
Desonide is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Desonide is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Atopic dermatitis, Contact dermatitis, Seborrheic dermatitis.
At a glance
| Generic name | topical desonide hydrogel 0.05% |
|---|---|
| Also known as | Desonide gel |
| Sponsor | Wake Forest University |
| Drug class | Topical corticosteroid (low-to-medium potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Desonide exerts its anti-inflammatory effects by activating glucocorticoid receptors in skin cells, which leads to reduced production of inflammatory mediators and cytokines. The hydrogel formulation provides enhanced penetration and sustained delivery to affected skin areas. This results in decreased erythema, pruritus, and other signs of dermatitis.
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Seborrheic dermatitis
- Other inflammatory skin conditions responsive to topical corticosteroids
Common side effects
- Skin atrophy
- Burning or stinging at application site
- Pruritus
- Folliculitis
Key clinical trials
- Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- topical desonide hydrogel 0.05% CI brief — competitive landscape report
- topical desonide hydrogel 0.05% updates RSS · CI watch RSS
- Wake Forest University portfolio CI